This research paper explores deliberative processes to enhance decision quality in health technology assessments, suggesting improved public healthcare outcomes.
This Research Paper is part of the CHE Research Paper Series. Results and ideas reported in Research Papers may not necessarily represent a final statement of the relevant research. Work reported in some Research Papers should be seen as work in progress and may not have been subject to peer review at the time of publication. This is CHE RP 202 and it is an early version of a paper intended for later submission to an academic journal. Abstract Health technology assessment increasingly relies on formal tools such as cost-effectiveness analysis, Quality-Adjusted Life-Years (QALYs), thresholds and structured evidence reviews. These tools are indispensable, but they cannot by themselves settle questions of relevance, interpretation, fairness, implementation or public justification. We argue that deliberative processes in health technology assessment matter not because deliberation is inherently virtuous, nor because algorithms are unhelpful, but because decisions about health technologies involve heterogeneous evidence, contested values, uncertainty and context-sensitive trade-offs that cannot responsibly be resolved by algorithm alone. The paper is organised around two linked tasks. The first is conjectural: to identify when deliberation is likely to be useful by distinguishing it from algorithmic reasoning, consultation and commenting, and by explaining why evidence does not combine itself into guidance. The second is evaluative: to propose tests for judging whether deliberation improves, or is likely to improve, decision quality. On our account, a better decision is one that is more comprehensively evidence-informed, better matched to the context of application, more efficiently implementable and more widely acceptable to those affected by it, whether positively or negatively. We further argue that deliberation may be ethically constitutive of legitimacy in public healthcare decision making, since allocation decisions require reasons that are public, contestable and defensible. We conclude by setting out a future agenda concerned with comparing deliberative and alternative processes, assessing their cost-effectiveness, building case-based institutional memory, improving stakeholder involvement and making anonymous opportunity cost victims more visible.
No takes yet. Share an insight, caveat, or question.
Küçükuncular et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: